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ABSTRACT
Brain metastasis is increasingly common, affecting
20%–40% of cancer patients. After diagnosis, survival
is usually limited to months in these patients. Treatment
for brain metastasis includes whole-brain radiation
therapy, surgical resection, or both. These treatments
aim to slow progression of disease and to improve or
maintain neurologic function and quality of life.
Although less common, primary brain tumours pro-
duce symptoms that are similar to those of brain metas-
tasis. Glioblastoma, the most common malignant tumour
of the brain, has a median survival of less than 12 months.
Patients are often treated with surgical resection fol-
lowed by radical radiation therapy and chemotherapy.
Here, we present 2 separate cases of lesions in
the brain radiologically compatible with brain metas-
tasis. In both cases, no primary cancer site had been
established, and neurosurgical intervention was sought
to obtain a pathologic diagnosis. Both cases were
pathologically confirmed as glioblastoma. These
cases demonstrate the importance of differentiation
between brain metastases and primary brain tumours
to ensure that the appropriate management strategy
is implemented.
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1. CASE PRESENTATION
1.1 Case 1
A 63-year-old woman attended the emergency depart-
ment with increased confusion and speech difficulty. She
reported several episodes of aphasia occurring before
this visit, with no history of headaches or seizures. Com-
puted tomography (CT) imaging showed 2–3 lesions in
the posterior temporal lobe, with accompanying edema
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[Figure 1(A)]. The multiplicity of lesions was reported
to likely represent metastases.
The patient was referred to a local medical on-
cologist, who began an extensive investigation for the
primary cancer site. The patient was prescribed dex-
amethasone, which improved her symptoms signifi-
cantly within 2 days. The patient was then referred for
whole-brain radiation therapy (WBRT), pending primary
cancer diagnosis. Investigation by the medical oncolo-
gist failed to reveal a primary cancer site. The patient
was referred to a neurosurgeon for tissue diagnosis to
guide the future use of systemic therapy. She under-
went a left temporal partial craniotomy for excision of
the tumour. Biopsy of the lesion showed evidence of
glioblastoma multiforme (Figure 2).
Following the excisional biopsy, the patient began
concurrent chemotherapy and radical radiation to the
brain. Imaging by CT revealed evidence of residual tu-
mour post-surgery [Figure 1(B)]. Radiotherapy was
given postoperatively. A parallel opposed pair of beams
was used to deliver 37.5 Gy in 15 fractions to a field
encompassing the surgical bed, residual tumour, and
edema with a 1-cm to 2-cm margin. A conformal boost
FIGURE 1   Post-contrast computed tomography (A) before resection
demonstrates a part-solid, part-cystic, ring-enhancing lesion in the
left temporal lobe; (B) immediately following resection demonstrates
a resection cavity containing air and fluid without an enhancing
abnormality (left frontal postsurgical pneumocephalus); (C) 2 months
post-resection demonstrates expansion of ring enhancement within
the left temporal lobe, associated with increased perilesion edema
and mass effect.CAMPOS et al.
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based on CT and volumetric enhanced magnetic reso-
nance imaging (MRI) scan acquired during the third
week of treatment [Figures 3(A, B)] followed. The
boost volume was the enhancing volume as interpreted
from the MRI slices, without a margin. The 17.5-Gy
boost was delivered in 7 fractions. The patient concur-
rently received temozolomide chemotherapy over 42
days, beginning on the first day of radiotherapy. She
experienced some side effects from the chemotherapy,
including pancytopenia and dysphagia secondary to mu-
cositis and thrush.
About 2 months after her initial diagnosis, the pa-
tient presented again with aphasia and confusion. The
CT conducted at this time showed progression of gliob-
lastoma tumour in the left temporal lobe [Figure 1(C)].
The patient was referred to a palliative care physician
in her community. Unfortunately, she passed away
shortly thereafter: 3 months after initial presentation,
and 2 months after tumour resection.
1.2 Case 2
A 62-year-old woman presented to the emergency de-
partment with severe right-sided headache and visual
scotomata. Imaging by CT showed at least 3 ring-en-
hancing lesions in the right cerebral hemisphere of the
brain, with associated edema. The multifocal nature
of these lesions was more in keeping with metastasis
than with primary malignancy. Because no evidence
of a primary malignancy was found at any other site,
the patient was referred to a neurosurgeon for biopsy
of one of the more accessible tumours. The pathologic
diagnosis proved to be glioblastoma multiforme (Fig-
ure 4). A MRI investigation showed a total of 5 ring-
enhancing lesions in the right hemisphere, with a mild
amount of local mass effect and no midline shift [Fig-
ure 5(A–F)].
The patient underwent radiotherapy (50 Gy deliv-
ered using a parallel opposed pair of lateral brain fields)
in 25 fractions over 5 weeks. Shortly after starting her
course of radiotherapy, the patient was put on an
adjuvant course of temozolomide that continued
throughout her radiotherapy.
2. DISCUSSION
Glioblastoma and other gliomas are the most common
type of primary brain tumour 1, with an incidence of 5
in 100,000 in the U.S. population 2. This frequency in-
creases in older adults: the mean age of onset for gliob-
lastoma is 53 years 3. Patients with primary brain
tumours commonly present with one or more symp-
toms that can include seizures (either partial or gen-
eral in nature), increased intracranial pressure, or
localized neurologic deficits such as weakness, motor
problems, and aphasia 3.
Although the predominant presenting symptom in
brain metastasis is headache 4, many patients have been
reported to experience symptoms very similar to those
seen with primary brain tumours. Specifically, esti-
mates suggest that 50% of patients with brain metasta-
sis have motor or language deficits 5, and 10%–15%
FIGURE 2   Pathology slide of glioblastoma multiforme (case 1). A
section stained with hematoxylin and eosin shows frank atypia in this
astrocytic tumour. Brisk mitotic activity is noted (arrows).
FIGURE 3   Volumetric (A) post-gadolinium T1 and (B) FLAIR (fluid-
attenuated inversion recovery) sequences 3 weeks post-resection,
demonstrating a left temporal craniotomy, with a combination of
underlying postsurgical changes and residual enhancing lesion
surrounded by infiltrative edema.
FIGURE 4   Pathology slide of glioblastoma multiforme (case 2). Some
of the classic features of anaplastic astrocytoma are illustrated:
nuclear pleomorphism, palisading necrosis (P) and brisk mitotic
activity (arrows).DIAGNOSIS OF PRIMARY AND METASTATIC BRAIN TUMOUR
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present with seizures 4,5. Approximately 10% of pa-
tients with brain metastasis are asymptomatic, and the
disease spread is identified through routine imaging 5.
Brain metastasis is evident in up to 40% of all cancer
patients 6–10, and overall, metastasis is more common
than primary brain tumour, affecting 12 in 100,000
Americans 6–10.
The preferred modality for detecting brain lesions,
whether they originate from primary brain cancer such
as glioblastoma or whether they are metastatic lesions
originating from other primary sites, is MRI with con-
trast administration 3,11–14. Despite the accuracy of
MRI, CT imaging is often used when MRI is either not
available or not suitable for the individual case 7,14,15.
The argument has been made that the availability, ef-
ficiency, and cost-effectiveness of CT imaging make it
the technique of choice in detecting brain lesions 16.
Pearl et al. suggested that non-contrast CT should be
the initial investigation to detect any hemorrhage or cal-
cification, followed by a double-contrast CT to identify
lesions 16. However, MRI has the advantage of produc-
ing multi-planar images with higher contrast 15. Images
produced by T2 weighted MRI are also more sensitive
to smaller lesions 14. Srikanth et al. reported a correla-
tion between the histologic and morphologic features of
tumours shown on both MRI and CT imaging 15.
Despite the advanced sensitivity of MRI, 11% of
patients with a brain lesion are given a false-positive
diagnosis, based solely on MRI, of either metastatic or
primary cancer 17,18. More recently, techniques such
as perfusion MRI have been used to differentiate pri-
mary gliomas and brain metastasis 19. Often, diagno-
sis of brain lesions must be confirmed by pathology
and histology examination, using excisional biopsy of
the tumour 3.
The appearance of lesions on MRI or CT imaging
will not always lead to a specific diagnosis. Even after
examination of multiple images, diagnosis depends on
many other factors. If the lesion is indicative of cancer,
radiologists and oncologists must determine whether the
lesion is a primary brain tumour, such as glioblastoma,
or metastasis from a non-localized site elsewhere in
the body. Approximately 80% of brain metastasis cases
are diagnosed in patients who already have a known
primary site of cancer 4. This metachro-nous presenta-
tion makes the differential diagnosis less difficult. In
cases of synchronous presentation, patients are diagnosed
with a primary cancer around the same time that their
brain metastasis is discovered. But before a primary
site is found, it can be very unclear whether brain le-
sions are metastatic or not. Furthermore, for up to 15%
of patients diagnosed with brain metastasis, the primary
cancer site will remain unknown despite thorough in-
vestigation 5. Positron-emission tomography imaging is
a good tool for detecting an unknown primary when brain
metastasis is suspected 20.
Advances in radiologic imaging, including MRI,
have made the differential diagnosis between cancer-
ous and non-cancerous lesions much easier. Before
making a diagnosis of cancer, radiologists look for sev-
eral features unique to lesions. However, the appear-
ance of primary brain tumours and of brain metastases
is often quite similar, making it difficult to distinguish
between them, especially when considering only a sin-
gle image. On MRI slices, metastatic lesions often ap-
pear as small, well-defined, ring-enhancing lesions
surrounded by edema 14,16. They may also show cen-
tral necrosis or hemorrhage, or both 16. Gliomas are
also found to have central necrosis surrounded by a
ring of contrast enhancement; they also usually present
with edema having mass effect 3. A recent study com-
paring the appearance of brain lesions, including those
caused by non-cancerous disease, found that 40% of
ring-enhancing lesions on MRI slices were caused by
gliomas and that 30% were associated with brain me-
tastasis 21. Lesions caused by metastasis and gliomas
were also found to have similar rates of hypo-intense
borders on T2 weighted MRI and to have similar rates
of heterogeneous centres or central necrosis 21.
New techniques in imaging are constantly emerg-
ing. One study showed that, as observed through
perfusion MRI, measurements of relative cerebral blood
volume of the edema associated with metastasis were
significantly lower than such measurements associated
with glioma 19.
Another factor that can significantly affect a dif-
ferential diagnosis of brain lesions is the location and
number of lesions. An estimated 20%–40% of cancer
patients will develop multiple brain metastases 22, as
FIGURE 5   Magnetic resonance imaging slices showing glioblastoma
multiforme (case 2). (A–C) Axial T1 post-gadolinium images and
(D–F) corresponding axial FLAIR (fluid-attenuated inversion recovery)
slices at the same levels. Ring-enhancing masses can be seen in (A)
the right temporal lobe, (A) right occipital lobe, (B) right inferior
parietal lobe, (C) right frontal lobe, and (C) right superior parietal
lobe. Under FLAIR, hyperintensity can be seen around each lesion (D–
F). Additional FLAIR hyperintensity is seen intervening between the
right frontal lobe and the right superior parietal lobe lesions (F).CAMPOS et al.
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compared with the 30%–40% that will develop a sin-
gle brain metastasis 23. Solitary brain lesions have been
found to be metastatic in only 15% of patients with an
unknown primary site 24. A recent study that compared
brain lesion images found a significant difference be-
tween the prevalence of multiple lesions in brain me-
tastasis (55%) and in glioma (23%) 20. Furthermore, in
glioma, non-localized multifocal lesions are rare; con-
tinuity between lesions occurs in all but 5% of cases 3.
Often, water diffusivity surrounding the tumour site is
taken into account. Significantly different values for
the apparent diffusion coefficient are reported in the
region of FLAIR (fluid-attenuated inversion recovery)
hyperintensity surrounding ring-enhancing lesions
caused by brain metastases and by gliomas 25. For these
reasons, multiple brain lesions are clearly much more
suspicious for brain metastasis than are single lesions.
However, to produce a diagnosis, care must be taken
in the analysis of the radiologic evidence and of the
symptoms. Ideally, pathology evidence should be ob-
tained through biopsy for a confirmed diagnosis.
Symptoms and presentation of brain metastasis and
glioblastoma can be quite similar, but patient progno-
sis can be quite different. The survival of patients with
brain metastasis often depends on the primary site, but
is usually about 12 weeks 6. With WBRT, survival in-
creases to 3–6 months in most patients 6. Patients with
completely untreated brain metastasis have a median
survival of only 4 weeks 11,12.
A recent clinical guideline outlined surgical resec-
tion followed by WBRT as the optimal treatment for
brain metastasis 26. Typically, surgical resection is
considered only for patients with a single, surgically
accessible lesion; with good performance status; and
with a minimum of metastasis sites elsewhere 26.
Postoperatively, WBRT aims to reduce the incidence of
tumour recurrence 26. In patients with multiple
metastases, WBRT is given, usually in doses of 30 Gy
in 10 fractions or 20 Gy in 5 fractions 26. Radiosurgical
boosts may improve survival in patients with single
lesions not eligible for surgery 26. Chemotherapy re-
mains an experimental treatment for brain metastasis,
and supportive care is often a viable option. However,
it is unclear which patients will benefit most from sup-
portive care 26.
Glioblastoma has one of the worst 5-year survival
rates of all primary cancers 27, with most studies re-
porting 4%–5% survival at 5 years 28. One recent study
found that the survival rates are actually overstated,
with the true 5-year survival rate being closer to 2% 28.
The median survival for glioblastoma patients is usu-
ally less than 12 months 29. Treatment can significantly
improve survival, quality of life, and neurologic symp-
toms in these patients. Surgical resection of as much
of the tumour as possible usually provides quick relief
of symptoms and possibly a confirmed diagnosis, but
the effect of surgical resection on survival is not con-
firmed 30. Radiotherapy has been shown to significantly
improve survival 31 and is given in much higher doses
than it is in brain metastasis patients. The maximum
safe dose varies between 58–60 Gy in fractions of 1.2–
2.0 Gy 3. When this treatment is given instead of WBRT,
it is usually concentrated at the site of the tumour 3.
Chemotherapy can be given instead of, or in combina-
tion with, radiotherapy. Alone, it has been reported to
increase survival by about 6% and to provide a 15%
reduction in overall risk of death 32. Overall survival
was improved in patients receiving radiotherapy with
adjuvant chemotherapy as compared with patients re-
ceiving radiotherapy alone 33.
In a recent phase III clinical trial, the European
Organization for the Research and Treatment of Can-
cer and the National Cancer Institute of Canada com-
pared survival in glioblastoma patients treated with
radiotherapy and concomitant and adjuvant temo-
zolomide with survival in patients treated with radio-
therapy alone. Results showed a significantly increased
2-year survival in the patients who received temo-
zolomide (27%) as compared with the patients who
received radiotherapy alone (10%) 34. Temozolomide
has proved to be a remarkably promising chemothera-
peutic agent in glioblastoma, but the optimal dosing
and route of administration of the drug have yet to be
determined 34.
3. CONCLUSIONS
Optimal treatment regimens in glioblastoma and in brain
metastasis differ greatly. A good prognosis in both groups
of patients depends on appropriate disease management.
If the diagnosis is erroneous, neither group of patients
will receive the care they need for improved survival
and quality of life. Further, they may suffer unneces-
sary side effects induced by suboptimal treatment. Given
the similar nature of both the symptoms and the pre-
senting appearance of cancerous brain lesions, diagnoses
are easily interchanged. It is therefore extremely im-
portant to exercise caution when diagnosing cancerous
brain lesions. Many factors, including imaging, symp-
toms, number and nature of lesions, and patient history
need to be taken into account. Pathologic evidence should
be obtained whenever possible.
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